Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. - Modi S; Jacot W; Iwata H; Park YH; Vidal Losada M; Li W; Tsurutani J; Ueno NT; Zaman K; Prat A; Papazisis K; Rugo HS; et al. (Nature medicine, 2025)